Newleos

Executive Summary

Newleos Therapeutics is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing novel small molecule treatments for neuropsychiatric disorders. Founded in 2021 by Longwood Fund and seasoned CNS drug development leaders, the company's pipeline is exclusively licensed from Roche, leveraging well-validated targets and optimized molecules. Newleos aims to address the significant unmet need in mental health by developing therapies with innovative mechanisms of action that reduce side effects and improve patient outcomes. The company's lead program is in Phase 1 clinical development, targeting a receptor system implicated in mood and anxiety disorders. With a strong scientific foundation and experienced team, Newleos is positioned to advance new therapeutic options for conditions such as major depressive disorder and anxiety. The early-stage pipeline represents a promising opportunity to address the limitations of current treatments, including delayed onset of action and tolerability issues.

Upcoming Catalysts (preview)

• TBDPhase 1 data readout for lead asset60% success
• TBDInitiation of Phase 2 trial for lead program50% success
• TBDPotential partnership or licensing deal for pipeline expansion40% success